NASDAQ · RPID
Healthcare · Medical - Devices
$1.61
Up+$0.01 (+0.31%)
Updated Aug 28, 2026, 3:02 PM
SID Score
2.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
RPID closed at $1.61 after 21 trading sessions, down 23.70% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $1.67 | $1.68 | $1.61 | $1.61 | 134.5K |
| Aug 26, 2026 | $1.67 | $1.7199 | $1.60 | $1.67 | 91.09K |
| Aug 25, 2026 | $1.67 | $1.69 | $1.60 | $1.66 | 186.64K |
| Aug 24, 2026 | $1.68 | $1.71 | $1.62 | $1.66 | 200.53K |
| Aug 21, 2026 | $1.69 | $1.705 | $1.635 | $1.68 | 122.66K |
| Aug 20, 2026 | $1.70 | $1.74 | $1.64 | $1.67 | 323.18K |
| Aug 19, 2026 | $1.60 | $1.74 | $1.57 | $1.70 | 297.24K |
| Aug 18, 2026 | $1.57 | $1.64 | $1.52 | $1.56 | 94.91K |
| Aug 17, 2026 | $1.69 | $1.7328 | $1.545 | $1.55 | 454.7K |
| Aug 14, 2026 | $1.72 | $1.77 | $1.66 | $1.68 | 287.02K |
| Aug 13, 2026 | $1.70 | $1.735 | $1.66 | $1.70 | 89K |
| Aug 12, 2026 | $1.71 | $1.7301 | $1.645 | $1.69 | 105.85K |
| Aug 11, 2026 | $1.72 | $1.79 | $1.64 | $1.69 | 234.79K |
| Aug 10, 2026 | $1.76 | $1.77 | $1.58 | $1.71 | 316.4K |
| Aug 7, 2026 | $2.00 | $2.00 | $1.66 | $1.73 | 1.44M |
| Aug 6, 2026 | $2.10 | $2.11 | $2.05 | $2.08 | 72.19K |
| Aug 5, 2026 | $2.11 | $2.12 | $2.09 | $2.11 | 29.82K |
| Aug 4, 2026 | $2.16 | $2.18 | $2.015 | $2.06 | 198.55K |
| Aug 3, 2026 | $2.16 | $2.1999 | $2.04 | $2.12 | 119.04K |
| Jul 31, 2026 | $2.10 | $2.14 | $2.0701 | $2.13 | 20.56K |
| Jul 30, 2026 | $2.06 | $2.15 | $2.05 | $2.11 | 127.6K |
The latest Smart Investors Daily articles mentioning RPID.
RPID research
Company profile and research snapshot.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 29, 2026 | Keybanc | Overweight | — |
| May 22, 2026 | Lake Street | Buy | — |
| Jul 28, 2025 | Lake Street | Buy | — |
| Feb 12, 2025 | Keybanc | Overweight | — |
| Mar 7, 2023 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Yahoo · Aug 19, 2026
The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Yahoo · Aug 14, 2026
Record gross margins and 200th system milestone signal momentum toward profitability.
Yahoo · Aug 7, 2026
Moby summary of Rapid Micro Biosystems, Inc.'s Q2 2026 earnings call
Yahoo · Aug 7, 2026
Company exceeds Q2 guidance with 11% revenue growth and record gross margin, while reaffirming full-year outlook and advancing key partnerships.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning RPID.
